Drug Delivery Platforms
•230 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (230)
| Company | Market Cap | Price |
|---|---|---|
|
QNRX
Quoin Pharmaceuticals, Ltd.
Invisicare-based drug-delivery platform is used for QRX003 and other topical formulations, constituting a major product/technology platform.
|
$10.57M |
$10.82
+1.55%
|
|
GELS
Gelteq Limited Ordinary Shares
Gelteq's core offering is a gel-based drug delivery platform used across nutraceuticals, pet care, sports, OTC, and pharmaceutical products.
|
$9.82M |
$1.05
-15.32%
|
|
PULM
Pulmatrix, Inc.
Pulmatrix's core offering is the iSPERSE dry powder drug delivery platform, a direct product category.
|
$9.59M |
$2.67
+5.53%
|
|
IMNN
Imunon, Inc.
TheraPlas is a drug delivery platform enabling loco-regional cytokine production.
|
$9.10M |
$4.16
+0.73%
|
|
SCNX
Scienture Holdings, Inc.
SCNX emphasizes novel formulations and delivery platforms (drug delivery platforms) as a competitive edge.
|
$8.55M |
$0.52
-0.54%
|
|
BCDA
BioCardia, Inc.
Helix is BioCardia's proprietary transendocardial biotherapeutic delivery system, a core drug-delivery platform the company uses to administer its cell therapies.
|
$8.41M |
$1.46
+0.34%
|
|
RNAZ
TransCode Therapeutics, Inc.
TTX is a proprietary drug delivery platform for RNA therapeutics, enabling tumor targeting and intracellular delivery.
|
$7.45M |
$8.77
-0.74%
|
|
ALZN
Alzamend Neuro, Inc.
AL001 uses a patented ionic cocrystal drug-delivery platform to improve brain lithium delivery.
|
$7.38M |
$2.33
+3.78%
|
|
PHIO
Phio Pharmaceuticals Corp.
INTASYL is described as a self-delivering drug delivery platform for gene silencing.
|
$6.53M |
$1.14
+0.44%
|
|
ENTO
Entero Therapeutics, Inc.
Adrulipase is delivered via a capsule-based drug delivery approach; tag Drug Delivery Platforms captures the delivery modality as a core product attribute.
|
$6.23M |
$2.96
-25.25%
|
|
PMCB
PharmaCyte Biotech, Inc.
PMCB's encapsulation technology is a drug-delivery platform enabling localized prodrug activation.
|
$6.05M |
$0.90
-3.61%
|
|
SNGX
Soligenix, Inc.
Multiple proprietary platforms (HyBryte PDT, IDR, ThermoVax) represent drug delivery platforms.
|
$6.04M |
$1.41
+5.22%
|
|
MBRX
Moleculin Biotech, Inc.
MBRX utilizes liposomal drug delivery formulations for Annamycin, aligning with Drug Delivery Platforms as a major capability.
|
$6.03M |
$5.04
+0.80%
|
|
CELZ
Creative Medical Technology Holdings, Inc.
ImmCelz/AlloStem platform could be considered a Drug Delivery Platform for cell therapies.
|
$5.16M |
$2.02
+6.32%
|
|
CLDI
Calidi Biotherapeutics, Inc.
Drug Delivery Platforms are at the core of RedTail/NeuroNova/SuperNova, enabling systemic delivery of therapeutic payloads to tumors.
|
$4.92M |
$1.02
-1.92%
|
|
KALA
KALA BIO, Inc.
MSC-S platform represents a drug delivery platform for cell-free therapies.
|
$4.74M |
$0.67
+10.80%
|
|
TTNP
Titan Pharmaceuticals, Inc.
Titan's core ProNeura technology is a long-acting drug delivery platform used for subdermal implants.
|
$4.21M |
$4.61
|
|
SONN
Sonnet BioTherapeutics Holdings, Inc.
FHAB constitutes a proprietary drug delivery platform intended to extend half-life and improve tumor targeting of biologics.
|
$3.99M |
$1.28
+1.98%
|
|
OGEN
Oragenics, Inc.
ONP-002 uses a proprietary intranasal drug-delivery platform (powder formulation + breath-propelled device).
|
$3.77M |
$0.95
+2.56%
|
|
PHGE
BiomX Inc.
BiomX leverages a drug delivery platform (BOLT) to rapidly assemble phage cocktails and targeted therapies.
|
$3.74M |
$2.60
-0.38%
|
|
LADX
LadRx Corporation
LADR is a proprietary drug delivery platform used to target tumors and release payloads.
|
$3.70M |
$0.11
|
|
SILO
Silo Pharma, Inc.
Drug Delivery Platforms directly describes Silo's intranasal and implantable drug delivery technologies (SPC-15, SPC-14, SP-26).
|
$3.55M |
$0.38
-1.00%
|
|
LYRA
Lyra Therapeutics, Inc.
XTreo drug-delivery platform is Lyra's core product, enabling six months of localized drug therapy via in-office implant (LYR-210).
|
$3.27M |
$1.98
+1.54%
|
|
BICX
BioCorRx Inc.
BICX104 comprises a biodegradable, sustained-release naltrexone implant, representing a drug-delivery platform.
|
$2.65M |
$0.40
|
|
CLSD
Clearside Biomedical, Inc.
Clearside's core offering is a drug delivery platform enabling suprachoroidal (eye) delivery and extended-release formulations.
|
$2.15M |
$0.43
+4.90%
|
|
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
The company references a proprietary platform designed to enhance drug delivery for radiation sensitization, indicating a drug delivery platform.
|
$1.98M |
$1.79
-2.97%
|
|
REVB
Revelation Biosciences, Inc.
Gemini is a drug-delivery platform formulation used across multiple indications, matching Drug Delivery Platforms.
|
$1.61M |
$0.95
+6.12%
|
|
NLSP
NLS Pharmaceutics AG
The company relies on proprietary drug-delivery platforms (extended-release mazindol formulation and DOXA platform) to optimize therapeutic profiles.
|
$745651 |
$0.79
-67.48%
|
|
PLRZ
Polyrizon Ltd.
Polyrizon's core offering is a proprietary intranasal hydrogel-based drug delivery platform (Capture & Contain and Trap & Target) used to deliver allergy blockers and CNS-targeted APIs.
|
$43478 |
$15.54
|
|
NCNA
NuCana plc
ProTide is a proprietary drug-delivery platform used to enhance efficacy/safety of nucleoside analogs, a core differentiator for NuCana.
|
N/A |
$3.30
-1.20%
|
Showing page 3 of 3 (230 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
